273 related articles for article (PubMed ID: 18453724)
21. Coagulation and adulteration--building on science and policy lessons from 1905.
Avorn J
N Engl J Med; 2008 Jun; 358(23):2429-31. PubMed ID: 18525040
[No Abstract] [Full Text] [Related]
22. "Who's winning the human race?"Cold war as pharmaceutical political strategy.
Tobbell DA
J Hist Med Allied Sci; 2009 Oct; 64(4):429-73. PubMed ID: 19493917
[TBL] [Abstract][Full Text] [Related]
23. [Public health and chemical-pharmaceutical companies].
Ribeiro MA
Hist Cienc Saude Manguinhos; 2000 Nov-2001 Feb; 7(3):607-26. PubMed ID: 16683337
[TBL] [Abstract][Full Text] [Related]
24. The effects of government policy on drug use: Java, 1875-1904.
VanLuijk EW; VanOurs JC
J Econ Hist; 2001; 61(1):1-18. PubMed ID: 18468008
[No Abstract] [Full Text] [Related]
25. [Relationship between pharmaceutical industry and the French government during the last two centuries].
Bonnemain H; Bonnemain B
Rev Hist Pharm (Paris); 2002; 50(334):239-56. PubMed ID: 12378715
[TBL] [Abstract][Full Text] [Related]
26. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
27. America's first drug regulation regime: the rise and fall of the Import Drug Act of 1848.
Heath WJ
Food Drug Law J; 2004; 59(1):169-99. PubMed ID: 15212037
[No Abstract] [Full Text] [Related]
28. History of regulatory requirements for poultry biologics in the United States, 1970s to 1990s.
Espeseth DA; Lasher H
Avian Dis; 2013 Jun; 57(2):167-71. PubMed ID: 24689169
[TBL] [Abstract][Full Text] [Related]
29. Panel discussion on vaccine development to meet U.S. and international needs. When manufacturers are unwilling to accept the risks or invest the capital: vaccine production by the Salk Institute to specifications of the U.S. Army.
French GR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S309. PubMed ID: 7865328
[No Abstract] [Full Text] [Related]
30. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
Zalesky CD
J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
[TBL] [Abstract][Full Text] [Related]
31. The history of vaccines and immunization: familiar patterns, new challenges.
Stern AM; Markel H
Health Aff (Millwood); 2005; 24(3):611-21. PubMed ID: 15886151
[TBL] [Abstract][Full Text] [Related]
32. Why certain vaccines have been delayed or not developed at all.
Plotkin SA
Health Aff (Millwood); 2005; 24(3):631-4. PubMed ID: 15886153
[TBL] [Abstract][Full Text] [Related]
33. Organic solvents in the pharmaceutical industry.
Grodowska K; Parczewski A
Acta Pol Pharm; 2010; 67(1):3-12. PubMed ID: 20210074
[TBL] [Abstract][Full Text] [Related]
34. The policy outlook from the Hill.
Vastag B
Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381
[No Abstract] [Full Text] [Related]
35. Notes and comments "High and dry?" The Public Readiness and Emergency Preparedness Act and liability protection for pharmaceutical manufacturers.
Copper BK
J Health Law; 2007; 40(1):65-105. PubMed ID: 17549932
[TBL] [Abstract][Full Text] [Related]
36. The Orphan Drug Act: an engine of innovation? At what cost?
Rohde DD
Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
[No Abstract] [Full Text] [Related]
37. The great American medicine show revisited.
Tomes N
Bull Hist Med; 2005; 79(4):627-63. PubMed ID: 16327082
[TBL] [Abstract][Full Text] [Related]
38. A proposal for financing postmarketing drug safety studies by augmenting FDA user fees.
Carpenter D
Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-469-80. PubMed ID: 16234281
[TBL] [Abstract][Full Text] [Related]
39. Bush tails follow-ons.
Fox J
Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007
[No Abstract] [Full Text] [Related]
40. Vaccine supply, demand, and policy: a primer.
Muzumdar JM; Cline RR
J Am Pharm Assoc (2003); 2009; 49(4):e87-99. PubMed ID: 19589753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
